You are here: Industry Insights > Teplizumab

News List

Provention Bio Receives Complete Response Letter (CRL) to Biologics License Application (BLA) for Teplizumab for the Delay of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals drugs
July 21, 2021
Provention announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals.
FDA declines to approve Provention Bio’s teplizumab for diabetes pharmaceutical-technology
July 08, 2021
The US Food and Drug Administration (FDA) has declined to approve Provention Bio’s biologics licence application (BLA) for teplizumab in type 1 diabetes (T1D), an autoimmune disease.
Provention Bio wins FDA panel backing for teplizumab to delay type 1 diabetes firstwordpharma
May 31, 2021
An FDA advisory committee on Wednesday tipped in favour of recommending approval for Provention Bio's teplizumab to delay the onset of type 1 diabetes in at-risk individuals.
Experimental immunotherapy significantly delays onset of type 1 diabetes europeanpharmaceuticalreview
March 08, 2021
If approved for use, teplizumab could be the first drug able to delay the onset or completely prevent type 1 diabetes in at-risk groups.
Provention Bio Announces Teplizumab BLA for Delay or Prevention of Clinical T1D americanpharmaceuticalreview
January 11, 2021
Provention Bio announced the Biologics License Application (BLA) for teplizumab for the delay or prevention of clinical type 1 diabetes (T1D) in at-risk individuals has been filed by the U.S. Food and Drug Administration (FDA).
FDA approval of Provention Bio’s Teplizumab could bring first disease-modifying therapy to type 1 diabetes space expresspharma
November 27, 2020
If Provention Bio’s rolling Biologic License Application (BLA) submission to the FDA for teplizumab is approved, teplizumab will be the first disease-modifying therapy for type 1 diabetes (T1D).
Provention Bio Initiates Rolling Submission of BLA for Teplizumab for Type 1 Diabetes americanpharmaceuticalreview
April 17, 2020
Provention Bio announced the initiation of the rolling submission of the Company's Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for teplizumab (PRV-031).
ADA: Teplizumab Can Delay T1DM Progression in Those at Risk drugs
June 14, 2019
Teplizumab Can Delay T1DM Progression in Those at Risk.
Investigational Drug, Teplizumab, May Help Delay Onset of Type 1 Diabetes drugs
June 11, 2019
Investigational Drug, Teplizumab, May Help Delay Onset of Type 1 Diabetes.
Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes drugs
April 17, 2019
Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes.